Biocept Inc.
BIOCEPT INC (Form: 10-Q, Received: 11/10/2016 16:09:54)

 

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      .

Commission file number: 001-36284

 

Biocept, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

80-0943522

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

5810 Nancy Ridge Drive, San Diego, California

(Address of principal executive offices)

92121

(Zip Code)

(858) 320-8200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  (Do not check if a smaller reporting company)

  

Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes   No 

As of November 4, 2016, there were 17,499,397 shares of the Registrant’s common stock outstanding.

 

 

 

 

 


BIOCEPT, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

September 30, 2016

INDEX

 

 

 

 

  

Page

 

 

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS

  

3

 

 

 

PART I.

 

FINANCIAL INFORMATION

  

 

 

 

 

Item 1.

 

Financial Statements

  

4

 

 

 

 

 

Condensed Balance Sheets as of December 31, 2015 and September 30, 2016 (unaudited)

  

4

 

 

 

 

 

Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2016 (unaudited)

  

5

 

 

 

 

 

Condensed Statements of Cash Flows for the nine months ended September 30, 2015 and 2016 (unaudited)

  

6

 

 

 

 

 

Notes to Condensed Financial Statements (unaudited)

  

8

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

21

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures about Market Risk

  

28

 

 

 

Item 4.

 

Controls and Procedures

  

28

 

 

 

PART II.

 

OTHER INFORMATION

  

 

 

 

 

Item 1.

 

Legal Proceedings

  

29

 

 

 

 

 

Item 1A.

 

Risk Factors

  

29

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

  

31

 

 

 

Item 3.

 

Defaults Upon Senior Securities

  

31

 

 

 

Item 4.

 

Mine Safety Disclosures

  

31

 

 

 

Item 5.

 

Other Information

  

31

 

 

 

Item 6.

 

Exhibits

  

31

 

 

 

2


I MPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included or incorporated by reference in this Quarterly Report other than statements of historical fact, are forward-looking statements. You can identify these and other forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made except as required by law. Readers should, however, review the factors and risks we describe in the reports and registration statements we file from time to time with the SEC.

 

 

 

3


P ART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

Biocept, Inc.

Condensed Balance Sheets

 

 

 

December 31,

 

 

September 30,

 

 

2015

 

 

2016

 

 

 

 

 

 

(unaudited)

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

8,821,329

 

 

$

678,855

 

Accounts receivable

 

34,200

 

 

 

85,664

 

Inventories, net

 

349,271

 

 

 

497,517

 

Prepaid expenses and other current assets

 

435,938

 

 

 

499,133

 

Total current assets

 

9,640,738

 

 

 

1,761,169

 

Fixed assets, net

 

946,180

 

 

 

1,521,380

 

Total assets

$

10,586,918

 

 

$

3,282,549

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

632,538

 

 

$

1,700,383

 

Accrued liabilities

 

966,899

 

 

 

1,143,863

 

Supplier financings

 

42,369

 

 

 

48,880

 

Current portion of equipment financings

 

110,924

 

 

 

255,605

 

Current portion of credit facility

 

1,588,058

 

 

 

1,896,718

 

Total current liabilities

 

3,340,788

 

 

 

5,045,449

 

Non-current portion of equipment financings, net

 

291,189

 

 

 

572,096

 

Non-current portion of credit facility, net

 

2,638,487

 

 

 

1,593,220

 

Non-current portion of interest payable

 

153,547

 

 

 

209,914

 

Non-current portion of deferred rent

 

470,172

 

 

 

418,028

 

Total liabilities

 

6,894,183

 

 

 

7,838,707

 

Commitments and contingencies (see Note 11)

 

 

 

 

 

 

 

Shareholders’ equity/(deficit):

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 40,000,000 authorized; 6,556,685 issued and outstanding at December 31, 2015; 150,000,000 authorized; 8,399,397 issued and outstanding at September 30, 2016.

 

656

 

 

 

840

 

Additional paid-in capital

 

158,928,627

 

 

 

164,891,998

 

Accumulated deficit

 

(155,236,548

)

 

 

(169,448,996

)

Total shareholders’ equity/(deficit)

 

3,692,735

 

 

 

(4,556,158

)

Total liabilities and shareholders’ equity/(deficit)

$

10,586,918

 

 

$

3,282,549

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

4


Biocept, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

 

 

 

For the three months ended September 30,

 

 

For the nine months ended September 30,

 

 

2015

 

 

2016

 

 

2015

 

 

2016

 

Revenues:

$

164,856

 

 

$

1,047,280

 

 

$

391,626

 

 

$

1,931,509

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

1,159,710

 

 

 

1,876,288

 

 

 

3,320,467

 

 

 

5,020,649

 

Research and development expenses

 

677,729

 

 

 

600,613

 

 

 

2,073,391

 

 

 

2,044,968

 

General and administrative expenses

 

1,630,608

 

 

 

1,919,843

 

 

 

4,281,883

 

 

 

4,924,731

 

Sales and marketing expenses

 

1,055,653

 

 

 

1,278,455

 

 

 

2,616,218

 

 

 

3,875,063

 

Total costs and expenses

 

4,523,700

 

 

 

5,675,199

 

 

 

12,291,959

 

 

 

15,865,411

 

Loss from operations

 

(4,358,844

)

 

 

(4,627,919

)

 

 

(11,900,333

)

 

 

(13,933,902

)

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

(175,562

)

 

 

(154,869

)

 

 

(494,235

)

 

 

(393,029

)

Other income

 

38,412

 

 

 

38,412

 

 

 

64,020

 

 

 

115,236

 

Gain on sale of fixed assets

 

 

 

 

1,300

 

 

 

 

 

 

1,300

 

Total other income/(expense):

 

(137,150

)

 

 

(115,157

)

 

 

(430,215

)

 

 

(276,493

)

Loss before income taxes

 

(4,495,994

)

 

 

(4,743,076

)

 

 

(12,330,548

)

 

 

(14,210,395

)

Income tax expense

 

(199

)

 

 

 

 

 

(1,478

)

 

 

(2,053

)

Net loss and comprehensive loss

$

(4,496,193

)

 

$

(4,743,076

)

 

$

(12,332,026

)

 

$

(14,212,448

)

Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

6,242,604

 

 

 

8,370,691

 

 

 

5,245,303

 

 

 

7,549,663

 

Diluted

 

6,242,604

 

 

 

8,370,691

 

 

 

5,245,303

 

 

 

7,549,663

 

Net loss per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.72

)

 

$

(0.57

)

 

$

(2.35

)

 

$

(1.88

)

Diluted

$

(0.72

)

 

$

(0.57

)

 

$

(2.35

)

 

$

(1.88

)

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5


Biocept, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

 

 

For the nine months ended September 30,

 

 

2015

 

 

2016

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

Net loss

$

(12,332,026

)

 

$

(14,212,448

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

188,120

 

 

 

248,164

 

Inventory reserve

 

(20,277

)

 

 

(40,708

)

Stock-based compensation

 

1,016,266

 

 

 

1,164,979

 

Non-cash interest expense related to credit facility and other financing activities

 

93,454

 

 

 

60,951

 

Gain on sale of fixed assets

 

 

 

 

(1,300

)

Increase/(decrease) in cash resulting from changes in:

 

 

 

 

 

 

 

Accounts receivable

 

(29,760

)

 

 

(51,464

)

Inventories

 

(93,000

)

 

 

(107,538

)

Prepaid expenses and other current assets

 

(181,284

)

 

 

501,532

 

Accounts payable

 

142,028

 

 

 

991,846

 

Accrued liabilities

 

218,468

 

 

 

152,860

 

Accrued interest

 

96,295

 

 

 

58,684

 

Deferred rent

 

5,614

 

 

 

(22,839

)

Net cash used in operating activities

 

(10,896,102

)

 

 

(11,257,281

)

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

Proceeds from sale of fixed assets

 

 

 

 

1,300

 

Purchases of fixed assets

 

(118,896

)

 

 

(392,496

)

Net cash used in investing activities

 

(118,896

)

 

 

(391,196

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

Net proceeds from issuance of common stock and warrants

 

8,830,057

 

 

 

4,798,576

 

Proceeds from exercise of common stock warrants

 

9,697,660

 

 

 

 

Payments on equipment financings

 

(54,007

)

 

 

(86,336

)

Payments on supplier and other third party financings

 

(33,674

)

 

 

(427,934

)

Payments on line of credit

 

(247,701

)

 

 

(778,303

)

Net cash provided by financing activities

 

18,192,335

 

 

 

3,506,003

 

Net increase (decrease) in Cash and Cash Equivalents

 

7,177,337

 

 

 

(8,142,474

)

Cash and Cash Equivalents at Beginning of Period

 

5,364,582

 

 

 

8,821,329

 

Cash and Cash Equivalents at End of Period

$

12,541,919

 

 

$

678,855

 

Supplemental Disclosures of Cash Flow Information:

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

         Interest

$

309,324

 

 

$

282,142

 

         Taxes

$

2,054

 

 

$

2,053

 

 

Non-cash Investing and Financing Activities:

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on February 9, 2015, the closing of which occurred on February 13, 2015 (see Note 3). In connection with the closing of this offering, (i) warrants were issued to buy (in the aggregate) up to 2,666,666 shares of common stock at an exercise price of $4.68 per share with a term of five years and an estimated grant date fair value of approximately $7.7 million, which was recorded as an offset to additional paid-in capital within common stock issuance costs, (ii) the underwriters were granted a 45 day option from the closing date of this offering to purchase up to 400,000 additional shares of common stock at a price of $3.75 per share and/or additional warrants to purchase up to 400,000 shares of common stock at a price of $0.0003 per warrant, less underwriting discounts and commissions, to cover overallotments, if any, with an aggregate estimated grant date fair value of approximately $1.6 million that was recorded to common stock issuance costs, and (iii)

6


costs of $63,111 directly associated with this offering that were included in prepaid expenses and other current assets at December 31, 2014 were reclassified to common stock issuance costs .

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on April 29, 2016, the closing of which occurred on May 4, 2016 (see Note 3). In connection with the closing of this offering, warrants were issued to buy (in the aggregate) up to 1,163,526 shares of common stock at an exercise price of $3.90 per share with a term of five years and an estimated grant date fair value of approximately $2.0 million, which was recorded as an offset to additional paid-in capital within common stock issuance costs (see Note 4).

Fixed assets purchased totaling $279,008 and $631,232 during the nine months ended September 30, 2015 and 2016, respectively, were recorded as equipment financing obligations and were excluded from cash purchases in the Company’s unaudited condensed statements of cash flows. During the nine months ended September 30, 2016, a financing agreement underlying a fixed asset with a remaining net book value of $126,811, which was previously recorded as an equipment financing obligation, was cancelled.

The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statements of cash flows decreased from $19,546 at December 31, 2014 to $3,190 at September 30, 2015. The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statements of cash flows decreased from $64,300 at December 31, 2015 to $8,637 at September 30, 2016.

During the nine months ended September 30, 2016, the Company financed insurance premiums of $434,475 through third party financings.

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on October 14, 2016, the closing of which occurred on October 19, 2016 (see Note 13). In connection with the closing of this offering, warrants to purchase up to an aggregate of 9,100,000 shares of common stock with estimated grant date fair value of approximately $0.57 per share were issued, and a corresponding total of approximately $5.2 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any. Through the date that these unaudited condensed financial statements were available to be issued, the underwriters have exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. As of September 30, 2016, a total of $130,252 of costs directly associated with this offering were accrued and recorded in prepaid expenses and other current assets, of which none were paid as of September 30, 2016 and thus excluded from changes in both prepaid expenses and other current assets and accounts payable in the Company’s unaudited condensed statement of cash flows, and which were also subsequently reclassified to common stock issuance costs as an offset to additional paid in capital upon the closing of this offering.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

7


BIOCEPT, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

1. Basis of Presentation

Basis of Presentation

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.  

On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares . As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock, which was not affected by the one-for-three reverse stock split.

The Company and Business Activities

Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.

Recent Accounting Pronouncements

In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim

8


reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

9


 

2. Liquidity and Going Concern Uncertainty

As of September 30, 2016, cash and cash equivalents totaled $0.7 million and the Company had an accumulated deficit of $169.4 million. For the year and nine month periods ended December 31, 2015 and September 30, 2016, the Company incurred net losses of $16.9 million and $14.2 million, respectively. At September 30, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.3 million, of which approximately $2.2 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.8 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13).

Management’s Plan to Continue as a Going Concern

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

 

3. Sales of Equity Securities

Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, Inc., as underwriters named therein, a public offering of 2,666,666 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,666,666 shares of common stock was effected at a combined offering price of $3.75. The estimated grant date

10


fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closin g of this offering. All warrants sold in this offering have a per share exercise price of $4.68, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on Februa ry 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 mil lion after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 400,000 additional shares of common stock at a price of $3.75 per share and/or additional warrants to purchase up to 400,000 shares of common stock at a price of $0.0003 per warrant, less underwriting discounts and commissions, to cover overallotments, if any, which was not exercised. The estimated grant date fair value of the overallotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional no n-underwriter costs associated with this offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting the $0.9 million of underwriter costs and discounts and $0.3 million of additional non-un derwriter costs incurred, which were offset against these proceeds under applicable accounting guidance.

In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to Roth Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.3 million after deducting an estimated $0.3 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.7 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement.  On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement (see Note 13). Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that were issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company had the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 33,333 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either (i) the lowest sale price of the Company’s common stock on the purchase date, or (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submitted a purchase notice to Aspire Capital in an amount equal to 33,333 shares and the Company’s stock price was not less than $1.50 per share, the Company also had the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company could determine. The purchase price per share pursuant to such volume-weighted average price purchase notice was generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price was to be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the

11


purchase price. The Company could have delivered multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most re cent purchase had been completed. The common stock purchase agreement provided that the Company and Aspire Capital would not effect any sales on any purchase date where the closing sale price of the Company’s common stock was less than $1.50. There were no trading volume requirements or restrictions under the common stock purchase agreement, and the Company controlled the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital had no right to require any sales by the Company, but wa s obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There were no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of firs t refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 5 5,000 shares of its common stock. The common stock purchase agreement could have been terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital had agreed that neither it nor any of its agents, representative s and affiliates were to engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. The proceeds received by the Company under the common stock pu rchase agreement were used for working capital and general corporate purposes. During the nine months ended September 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds o f $544,051. Costs associated with this offering of approximately $42,000 and $83,000 during the year ended December 31, 2015 and nine months ended September 30, 2016, respectively, were also recorded to common stock issuance costs under applicable accounti ng guidance, and as such, the aggregate total increase in capital related to this transaction was approximately $1.4 million.

Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13).

 

4. Fair Value Measurement

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

Other Fair Value Measurements

As of the closing of the Company’s public offering in May 2016, the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions:

 

Stock price

$

2.70

 

Exercise price

$

3.90

 

Expected dividend yield

 

0.00

%

Discount rate-bond equivalent yield

 

1.23

%

Expected life (in years)

 

5.00

 

Expected volatility

 

90.0

%

The estimated fair value of the April 2014 Credit Facility at September 30, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

 

12


5. Balance Sheet Details

The following provides certain balance sheet details:

 

 

December 31,

 

 

September 30,

 

 

2015

 

 

2016

 

Fixed Assets

 

 

Machinery and equipment

$

2,518,158

 

 

$

2,707,601

 

Furniture and office equipment

 

143,726

 

 

 

143,726

 

Computer equipment and software

 

577,898

 

 

 

617,802

 

Leasehold improvements

 

514,614

 

 

 

517,968

 

Financed equipment

 

914,179

 

 

 

1,457,377

 

Construction in process

 

70,815

 

 

 

118,280

 

 

 

4,739,390

 

 

 

5,562,754

 

Less accumulated depreciation and amortization

 

3,793,210

 

 

 

4,041,374

 

Total fixed assets, net

$

946,180

 

 

$

1,521,380

 

Accrued Liabilities

 

 

 

 

 

 

 

Accrued interest

$

28,981

 

 

$

23,825

 

Accrued payroll

 

128,753

 

 

 

301,988

 

Accrued vacation

 

307,845

 

 

 

313,825

 

Accrued bonuses

 

376,100

 

 

 

318,237

 

Accrued sales commissions

 

76,574

 

 

 

97,844

 

Current portion of deferred rent

 

31,170

 

 

 

60,475

 

Accrued other

 

17,476

 

 

 

27,669

 

Total accrued liabilities

$

966,899

 

 

$

1,143,863

 

 

 

6. April 2014 Credit Facility

On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid.

On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. If on or before September 30, 2016 the Company received unrestricted net cash proceeds of at least $7.0 million from the issuance and sale its equity securities, or the Company received a signed letter of intent relating to a sale or merger of the Company, in form and substance satisfactory to the lender, the Company could have been required to make interest-only payments on the term loan through December 31, 2016, and the amount of the additional final payment to the lender upon repayment would have increased to $75,000, which did not occur. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the Company’s 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance.  

The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among

13


others, restrictions on transferring c ollateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain except ions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loa n under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due un der the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment a gainst the Company in an amount greater than $250,000.

A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% and 13.87% at December 31, 2015 and September 30, 2016, respectively.

 

7. Capital Lease Obligations

The Company leases certain laboratory equipment under arrangements classified as capital leases. The leased equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. Total gross value of fixed assets capitalized under such lease arrangements was $914,179 and $1,457,377 at December 31, 2015 and September 30, 2016, respectively. Total accumulated depreciation related to the leased equipment was approximately $523,000 and $616,000 at December 31, 2015 and September 30, 2016, respectively. Total depreciation expense for the leased equipment was approximately $24,000 and $40,000 for the three months ended September 30, 2015 and 2016, respectively, and was approximately $49,000 and $93,000 for the nine months ended September 30, 2015 and 2016, respectively. The weighted average effective annual interest rates related to the lease obligations are 13.35% and the maturity dates on outstanding arrangements range from July 2017 to May 2023.

The following schedule sets forth the future minimum lease payments, as well as corresponding laboratory equipment maintenance obligations that are not recorded as part of the leased equipment balances within fixed assets or capital lease obligations, outstanding under capital leases and due within each respective year ending December 31, and the present value of the minimum lease payments as of September 30, 2016:

 

Minimum

 

Maintenance

 

 

Lease

 

Obligation

 

 

Payments

 

Payments

 

2016

$

68,754

 

$

6,375

 

2017

 

238,287

 

 

25,440

 

2018

 

190,333

 

 

25,434

 

2019

 

155,388

 

 

24,676

 

2020

 

151,400

 

 

24,608

 

Thereafter

 

374,005

 

 

59,471

 

Total payments

 

1,178,167

 

 

166,004

 

Less amount representing interest

 

350,466

 

 

 

Present value of payments

$

827,701

 

$

166,004

 

At September 30, 2016, the present value of minimum lease payments due within one year was $255,605.

 

8. Stock-based Compensation

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The following per share amounts and share numbers have been adjusted for this reverse stock split as if it had occurred on January 1, 2015.

Equity Incentive Plans

The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 1,000,000 shares on a pre-reverse stock split basis, or 333,333 shares on a post-reverse stock split basis, of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide

14


period of non-employment, as a n inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. In conjunction with the one-for-three reverse split of the Company’s common stock effected on September 27, 2016, the num ber of non-inducement shares authorized under all plans decreased from 3,068,865 to 1,022,955 shares, and the number of inducement shares authorized under the 2013 Plan decreased from 1,000,000 shares to 333,333 shares. As of September 30, 2016, under all plans, a total of 1,022,955 non-inducement shares were authorized for issuance, 978,358 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 3,115 non-inducement shares were available for grant. As of September 30, 2016, a total of 333,333 inducement shares were authorized for issuance, 124,999 inducement stock options and RSUs had been issued and were outstanding, and 208,334 inducement shares were available for grant under the 2013 Plan.

Stock Options

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

Number of

 

 

Average Exercise

 

 

Contractual

 

 

Shares

 

 

Price Per Share

 

 

Term in Years

 

Vested and unvested expected to vest, December 31, 2015

 

646,900

 

 

$

15.48

 

 

 

9.0

 

Outstanding at December 31, 2015

 

713,659

 

 

$

11.23

 

 

 

9.0

 

Granted

 

276,628

 

 

$

2.60

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

Cancelled/forfeited/expired

 

(63,679

)

 

$

8.08

 

 

 

 

 

Outstanding at September 30, 2016

 

926,608

 

 

$

8.87

 

 

 

8.7

 

Vested and unvested expected to vest, September 30, 2016

 

838,037

 

 

$

9.37

 

 

 

8.1

 

 

The intrinsic values of options outstanding and options vested and unvested expected to vest at September 30, 2016 were both zero. The intrinsic value of options exercisable at September 30, 2016 was zero.

The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:

 

Stock and exercise prices

$1.57 - $4.02

 

Expected dividend yield

 

0.00

%

Discount rate-bond equivalent yield

0.99% – 1.39%

 

Expected life (in years)

5.13 – 6.08

 

Expected volatility

80.0% - 90.0%

 

15


Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2016 was $1.86 per share.

On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $4.40 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $2.87 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:

 

 

Percentage of

 

 

Overall Stock

 

 

Option Grants

 

 

Subject to Vesting

 

Target

 

 

 

Minimum number of accessions processed, billed and collected

 

13

%

Minimum revenues from contracts with pharmaceutical

   companies

 

10

%

Attainment of a sustainable positive GAAP gross  margin

 

12

%

Minimum operating cash on-hand with no more than one interim

   dilutive equity financing event

 

15

%

Achievement of the Company's 2016 corporate goals

 

25

%

Completion of a Board-approved strategic transaction

 

25

%

Total

 

100

%

On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which will vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vest upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction.

Restricted Stock

 

A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

Weighted

 

 

Number of

 

 

Average Grant

 

 

Shares

 

 

Date Fair Value

 

Vested and unvested expected to vest, December 31, 2015

 

15,369

 

 

$

14.49

 

Outstanding at December 31, 2015

 

25,752

 

 

$

15.12

 

Granted

 

165,829

 

 

$

1.96

 

Vested and issued

 

(4,449

)

 

$

16.05

 

Forfeited

 

(10,383

)

 

$

16.05

 

Outstanding at September 30, 2016

 

176,749

 

 

$

2.70

 

Vested and unvested expected to vest, September 30, 2016

 

172,550

 

 

$

2.71

 

The RSUs granted during the nine months ended September 30, 2016 vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. At September 30, 2016, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $277,496 and $270,904, respectively.

On June 12, 2014, the Company’s Board of Directors granted an RSU award for 14,832 shares with a grant date fair value of $16.05 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:

 

16


 

Percentage of

 

 

Overall RSU

 

 

Grant Subject to

 

 

Vesting

 

Target

 

 

 

Minimum revenue

 

25

%

Maximum EBITDA loss

 

15

%

Attainment of financial plan for fiscal 2015

 

20

%

Minimum value of strategic agreements

 

20

%

Implementation of four new diagnostic test panels

 

20

%

Total

 

100

%

During the nine months ended September 30, 2016, a total of 4,449 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 10,383 shares underlying this RSU were forfeited.

On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its Chief Executive Officer. Each of these retention RSUs has a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs.

Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company.

Stock-based Compensation Expense

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:

 

 

For the three months ended

 

 

For the nine months ended

 

 

September 30,

 

 

September 30,

 

 

2015

 

 

2016

 

 

2015

 

 

2016

 

Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

$

15,029

 

 

$

34,119

 

 

$

48,839

 

 

$

89,606

 

Research and development expenses

 

20,910

 

 

 

28,189

 

 

 

65,835

 

 

 

87,153

 

General and administrative expenses

 

257,404

 

 

 

292,381

 

 

 

706,026

 

 

 

829,516

 

Sales and marketing expenses

 

31,888

 

 

 

51,924

 

 

 

93,989

 

 

 

91,164

 

Total expenses related to stock options

 

325,231

 

 

 

406,613

 

 

 

914,689

 

 

 

1,097,439

 

RSUs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

 

 

14,918

 

 

 

 

 

 

16,834

 

Research and development expenses

 

1,625

 

 

 

14,131

 

 

 

10,724

 

 

 

15,583

 

General and administrative expenses

 

12,515

 

 

 

6,668

 

 

 

90,853

 

 

 

7,676

 

Sales and marketing expenses

 

 

 

 

22,939

 

 

 

 

 

 

27,447

 

Total stock-based compensation

$

339,371

 

 

$

465,269

 

 

$

1,016,266

 

 

$

1,164,979

 

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% and 0% - 8% per annum during the three and nine months ended September 30, 2015 and 2016, respectively. As of September 30, 2016, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,081,000 and is expected to be recognized over a weighted-average period of 2.1 years.

 

9. Common Stock Warrants Outstanding

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The summary of equity-classified common stock warrant activity has been adjusted for this reverse stock split as if it had occurred on December 31, 2015.

17


A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

Number of

 

 

Average Exercise

 

 

Contractual

 

 

Shares

 

 

Price Per Share

 

 

Term in Years

 

Outstanding at December 31, 2015

 

784,234

 

 

$

11.19

 

 

 

3.8

 

Issued

 

1,163,526

 

 

$

3.90

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

Expired

 

(50,904

)

 

$

30.00

 

 

 

 

 

Outstanding at September 30, 2016

 

1,896,856

 

 

$

6.21

 

 

 

4.1

 

 

The intrinsic value of equity-classified common stock warrants outstanding and exercisable at September 30, 2016 was zero.

 

10. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the nine months ended September 30, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on January 1, 2015.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

 

 

 

For the three and nine months ended

 

 

September 30,

 

 

2015

 

 

2016

 

Preferred warrants outstanding (number of common stock equivalents)

 

529

 

 

 

529

 

Preferred share RSUs (number of common stock equivalents)

 

24,384

 

 

 

 

Common warrants outstanding

 

797,579

 

 

 

1,896,856

 

Common share RSUs

 

25,752

 

 

 

176,749

 

Common options outstanding

 

684,779

 

 

 

926,608

 

Total anti-dilutive common share equivalents

 

1,533,023

 

 

 

3,000,742

 

 

11. Commitments and Contingencies

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

 

12. Related Party Transactions

All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 47,331 shares of the Company’s common stock and warrants to purchase up to an aggregate of 47,331 shares of its common stock for total gross proceeds of $177,500 (see Note 3).

A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the nine months ended September 30, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement.

Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable

18


secu rity deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $64,020 and $115,236 in rental income was recorded to other income in the Company’s unaudited condensed statements of operations and comprehensive loss during the nine months ended September 30, 2015 and 2016, respectively.

Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with the Company’s major stockholder, Claire K.T. Reiss, participated in its public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273 (see Note 3).

The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

 

13. Subsequent Events

Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million. The estimated grant date fair value of these warrants of approximately $0.57 per share, or a total of approximately $5.2 million, was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any. Through the date that these unaudited condensed financial statements were available to be issued, the underwriters have exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. The fair values of these overallotment options and all warrants issued in the October 2016 offering were estimated using Black-Scholes valuation models with the following assumptions:

 

 

Overallotment Options

 

 

Warrants

 

Stock price

$

0.93

 

 

$

0.93

 

Exercise price

$

1.0331

 

 

$

1.10

 

Expected dividend yield

 

0.00

%

 

 

0.00

%

Discount rate-bond equivalent yield

 

0.25

%

 

 

1.24

%

Expected life (in years)

 

0.08

 

 

 

5.00

 

Expected volatility

 

12.9

%

 

 

80.0

%

Seven members of the Company’s Board of Directors, including its Chief Executive Officer, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with the Company’s major shareholder, Claire K.T. Reiss, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999. The closing of the sale of these securities to the underwriters occurred on October 19, 2016, when the Company received, after deducting $0.6 million of underwriters’ discount and additional costs paid to the underwriters, $9.4 million of net cash proceeds. Subsequent to the closing of this offering on October 19, 2016 and through the date that these unaudited condensed financial statements were available to be issued, no additional cash proceeds had been received from the exercise of warrants sold in such offering. As such, the total increase in capital as a result of the sale of these shares and warrants is $8.8 million after deducting the $0.6 million of underwriter fees and costs and the estimated additional $0.6 million of non-underwriter costs incurred, which were offset against these proceeds under applicable accounting guidance.

Over the past several years the Company has generated operating losses in all jurisdictions in which it may be subject to income taxes. As a result, the Company has accumulated significant net operating losses and other deferred tax assets. Because of the Company’s history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized.

19


The Company does not expect to report a provision for income taxes until it has a history of earnings, if ever, that would support the realization of its deferred tax assets.

The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, the Company believes ownership changes likely occurred in both 2015 and 2016. As a result, the Company has estimated that the use of its net operating loss is limited and the remaining net operating loss carryforwards and research and development credits it estimates can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

On November 4, 2016, the Company voluntarily terminated the common stock purchase agreement that the Company entered into on December 21, 2015, with Aspire Capital. Pursuant to this common stock purchase agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement.


20


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2015 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on March 10, 2016. Past operating results are not necessarily indicative of results that may occur in future periods. The share numbers in the following discussion reflect a one-for-three reverse common stock split that we effected on September 27, 2016.

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” Our assays provide, and our planned future assays would provide, information to oncologists and other physicians that enable them to select appropriate personalized treatment for their patients who have been diagnosed with cancer based on timelier and more contemporaneous data on the characteristics of their patients’ tumors.

Our current assays and our planned future assays focus on key solid tumor indications utilizing our Target-Selector TM CTC offering for the biomarker analysis of CTCs and ctDNA from a standard blood sample. The Target-Selector CTC offering is based on an internally developed and patented, microfluidics-based capture and analysis platform, with enabling features that change how CTC testing is used by clinicians. The Target-Selector platforms provide both biomarker detection as well as monitoring capabilities, and require only a blood sample. Our patent pending Target-Selector ctDNA technology enables mutation detection with enhanced sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood, plasma, or cerebrospinal fluid. We believe the Target-Selector technology can someday be used as a stand-alone test for molecular biomarker screening, marked as in vitro diagnostics kits.

At our corporate headquarters facility located in San Diego, California, we operate a clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists. We manufacture our microfluidic channels, related equipment and certain reagents to perform our current assays and our planned future assays at this facility. CLIA certification is required before any clinical laboratory, including ours, may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, or treatment of disease or the assessment of health. The assays we offer and intend to offer are classified as laboratory developed tests, or LDTs, under CLIA regulations.

We are commercializing our Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, or NSCLC, small cell lung cancer, or SCLC, gastric cancer, colorectal cancer, prostate cancer, and melanoma. These assays utilize our dual CTC and ctDNA technology platform and provide biomarker analysis from a standard blood sample.

In the case of our breast and gastric cancer offering, biomarker analysis involves fluorescence in situ hybridization, or FISH, for the detection and quantitation of the human epidermal growth factor receptor 2, or HER2, gene copy number as well as immunocytochemical analysis of estrogen receptor, or ER, protein, as well as androgen receptor, or AR, protein, which are currently commercially available. We plan to include immunocytochemical analysis of progesterone receptor, or PR, proteins as part of the Target-Selector CTC menu in 2017. A patient’s HER2 status provides the physician with information about the appropriateness of therapies such as Herceptin® or Tykerb®. ER and PR status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors.

The lung cancer biomarker analyses currently include FISH testing for ALK, ROS1, RET, MET and FGFR1 gene rearrangements and mutation analysis of the T790M, Deletion 19, and L858R mutations of the epidermal growth factor receptor, or EGFR, gene as well as BRAF and KRAS using our Target-Selector ctDNA platform. The L858R mutation of the EGFR gene and Exon 19 deletions as activators of EGFR kinase activity are associated with the drugs Tarceva®, Gilotrif® and Iressa®. For lung cancer, we also offer a resistance panel assay consisting of the biomarkers MET, HER2 (both of which we perform using our technology for CTCs), KRAS, and T790M (both of which are performed using ctDNA in plasma). This assay could be used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with TKI therapy and therefore could qualify for inclusion in a clinical trial. In November 2015, Tagrisso® was approved by the U.S. Food and Drug Administration, providing another biomarker based therapy for the treatment of patients with EGFR related lung cancer. Tagrisso® is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.

Fibroblast growth receptor 1, or FGFR1, amplification is offered using our CTC technology. FGFR1 is present in several tumor types, including both NSCLC and SCLC and has been shown to be a prognostic indicator of progression. FGFR1 is also a key target for many drugs which are in clinical development.

21


Mutations of the BRAF gene are associated with Zelboraf® and Tafinlar®, which are both approved for treating patients with melanoma and are in clinic al trials for lung cancer. We offer testing for BRAF on blood using our ctDNA offering.

We recently analytically validated PD-L1 testing utilizing our CTC technology. PD-L1 is a biomarker that is informative for immuno-oncology therapies currently marketed today for lung cancer and melanoma, as well as in development for multiple tumor types. We collaborated with David Rimm, M.D., Ph.D., a pathologist at Yale Medical School, on the analytical development of this assay.

We plan to add other biomarker analyses, such as ESR1 and NRAS, on blood samples to our current assays and our planned future Target-Selector CTC assays as their relevance is demonstrated in clinical trials and/or included in guidelines used by physicians to make treatment decisions.

We continue to execute on our strategies of expanding our business globally as well as engaging with pharmaceutical companies on clinical trials and assay development. We have executed distribution agreements in Mexico with Quest Diagnostics to support testing for a large pharmaceutical partner, as well as an agreement with Progenetics to market our assays in Israel for clinical testing.

We announced three additional pharmaceutical collaborations during 2016. The first agreement is to provide testing for a clinical trial that includes patients who have leptomeningeal disease or metastatic lung cancer to the brain. In this exploratory trial, we are testing both cerebral spinal fluid and blood for molecular alterations that could be impacted by treatment. The second agreement is a large milestone-based multi-project assay development collaboration focused on hepatocellular carcinoma, or liver cancer, whereby we will develop assays utilizing both our CTC and ctDNA technologies for clinical trials. The third collaboration involves a study presented at the European Society for Medical Oncology, or ESMO, Annual Congress in October 2016, whereby collaborators from a large pharmaceutical company, as well as academic investigators, demonstrated a high concordance between our Target-Selector liquid biopsy and tissue biopsy. Subsequent to this study, we have earned business in both Mexico and Columbia for EGFR testing in blood to qualify patients for the pharmaceutical company’s targeted therapy.

Our revenue generating efforts are focused in three areas:

 

providing clinical testing that oncologists use in order to determine the best treatment plan for their patients;

 

providing clinical trial, research and development services to biopharma companies developing cancer therapies; and

 

licensing our proprietary testing and/or technologies to partners in the United States and abroad.

The following tables set forth certain information concerning our commercial cases accessioned for the periods shown:

 

 

Three Months Ended September 30,

 

 

Change

 

 

2015

 

 

2016

 

 

#

 

 

%

 

Commercial cases accessioned

 

443

 

 

 

1,023

 

 

 

580

 

 

 

131

%

 

 

Nine Months Ended September 30,

 

 

Change

 

 

2015

 

 

2016

 

 

#

 

 

%

 

Commercial cases accessioned

 

1,024

 

 

 

2,727

 

 

 

1,703

 

 

 

166

%

Revenues from commercial cases are recognized as collected, and the expected collection period for a commercial case often extends beyond the end of the quarter in which accessioned, with multiple payments received per case. For commercial accessions received during the nine months ended September 30, 2015 and 2016, the average number of tests performed increased from 2.4 tests per accession to 3.8 tests per accession, respectively. For commercial accessions received from January 1, 2016 through September 30, 2016, the expected price to be collected at 2016 Medicare schedule rates ranged from less than $200 per accession to over $5,000 per accession, and the weighted-average expected price to be collected is approximately $1,185 per accession, although such reimbursement experience has not yet been achieved. Relatively higher reimbursement rates are expected to be achieved for cases billed to certain private payors where we have agreements. Approximately 47% of the number of commercial accessions billed from January 1, 2016 through September 30, 2016 were subject to Medicare reimbursement rates, and approximately 50% and 45% of commercial revenues and total revenues, respectively, during the nine months ended September 30, 2016 were associated with Medicare reimbursement. We have not historically been reimbursed at these average rates for a variety of reasons, including billing challenges related to changes in Medicare CPT codes for our FISH assays in 2015, establishing our associated internal processes, and also managing an external “out-sourced” billing company. Additionally, a significant amount of our non-Medicare business (private payors) has historically not been contracted, and reimbursement for this business has historically not been at “in network” rates and has therefore been inconsistent. We did begin to contract private payor networks in 2015 and continue to do so in 2016, and our number of accessions treated as “in network” increased and reimbursement is improving. We are currently contracted with eight Preferred Provider Organization networks, one large health plan, and three regional Independent Physician Associations, and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans.

22


Results of Operations

Three Months Ended September 30, 2015 and 2016

The following table sets forth certain information concerning our results of operations for the periods shown:

 

 

Three Months Ended September 30,

 

 

Change

 

 

2015

 

 

2016

 

 

$

 

 

%

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

$

165

 

 

$

1,047

 

 

$

882

 

 

 

535

%

Cost of revenues

 

1,160

 

 

 

1,876

 

 

 

716

 

 

 

62

%

Research and development expenses

 

678

 

 

 

601

 

 

 

(77

)

 

 

(11

%)

General and administrative expenses

 

1,630

 

 

 

1,920

 

 

 

290

 

 

 

18

%

Sales and marketing expenses